Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T73255 |
Akt1-IN-1
|
||
Akt1-IN-1 是一种有效的 Akt1抑制剂,对 MIA Paca-2 细胞的 IC50为 18.79 nM。Akt1-IN-1 不具有明显的致畸性、肝毒性和心脏毒性 (有害作用剂量大于 100 µM)。Akt1-IN-1 可用于抗癌研究。 | |||
T14152 |
Akt1 and Akt2-IN-1
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM). It has potent and balanced activity. | |||
T79214 |
Tubulin/AKT1-IN-1
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
Tubulin/AKT1-IN-1 (Compound D1-1) 作为一种抑制剂,能够阻碍微管蛋白的聚合和AKT通路的激活。在抑制H1975细胞增殖和迁移方面表现出显著效果,同时轻度诱导细胞凋亡(apoptosis),适用于非小细胞肺癌(NSCLC)研究。 | |||
T72885 |
Akt1&PKA-IN-1
|
||
Akt1&PKA-IN-1 是一种有效的Akt/PKA 双重抑制剂,对 PKAa、Akt 和CDK2的IC50值分别为 0.03、0.11 μM 和 9.8 μM。Akt1&PKA-IN-1 对细胞周期蛋白依赖性激酶 2 (CDK2) 具有选择性。 | |||
T4444 |
A-674563 HCl (552325-73-2(free base))
|
ERK; Akt; PKA; CDK; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
A-674563 HCl (552325-73-2(free base)) 是一种口服的、ATP 竞争性的、可逆的 Akt 抑制剂(Akt1 的 Ki:11 nM)。它对 PKA 和 Cdk2 具有抑制活性(IC50:16/46 nM),但对 Akt1 的选择性比 CMGC、CAMK 和 TK 家族中的其他激酶高 10 至 >1800 倍。 | |||
T14860 |
CaMKII-IN-1
|
CaMK; Autophagy | Autophagy; Neuroscience |
CaMKII-IN-1是高效的 CaMKII 选择性抑制剂,IC50为63nM,对 CaMKIV, MLCK, p38a, Akt1,和 PKC 这些靶点几乎无作用。 | |||
T61680 | AKT-IN-5 | ||
AKT-IN-5 (Example 8) is a chemical compound known as an Akt inhibitor, specifically targeting Akt1 and Akt2. Its potency is reflected in IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively [1]. | |||
T22247 |
Miransertib (ARQ 092) HCl
|
||
Miransertib hydrochloride (ARQ-092 hydrochloride) is a powerful, orally bioavailable, selective, and allosteric inhibitor of Akt. It exhibits an inhibitory concentration (IC50) of 2.7 nM, 14 nM, and 8.1 nM against Akt1, Akt2, and Akt3, respectively. In addition to its Akt inhibitory activity, Miransertib hydrochloride also demonstrates significant potency as an inhibitor of the AKT1-E17K mutant protein. This compound shows promise in research related to PI3K/AKT-driven tumors and Proteus syndrom... | |||
T17346 | 9-Decyn-1-ol | Others | Others |
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker suitable for synthesizing PROTACs. It serves as a conjugation agent to combine GDC-0068 and Lenalidomide, resulting in the formation of INY-03-041. INY-03-041 is a potent and highly selective pan-Akt degrader that operates through the PROTAC mechanism. It effectively inhibits Akt1, Akt2, and Akt3 with IC50 values of 2.0 nM, 6.8 nM, and 3.5 nM, respectively[1]. | |||
T81784 |
MK-2206 free base
|
Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling |
MK-2206 free base是一种口服活性、高选择性的变构Akt抑制剂,IC50分别针对Akt1、Akt2、Akt3为8、12和65 nM 。多种乳腺癌细胞系、PIK3CA突变以及PTEN缺失细胞系对此化合物敏感,显示出抗癌活性。 | |||
T18065 |
Lenalidomide-C9-aldehyde
|
Others | Others |
Lenalidomide-C9-aldehyde is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a linker. Lenalidomide-C9-aldehyde can be used in the synthesis of a series of PROTACs, such as INY-03-041. INY-03-041 |